■抗纤维化治疗可减少特发性肺纤维化(IPF)患者的肺功能下降。这个单臂,开放标签,非随机研究旨在确定抗纤维化治疗对患者报告的症状和治疗预期的影响。
■52例确诊IPF患者,平均年龄为65±8.63岁(73%为男性),在基线和吡非尼酮治疗12个月后完成了以下调查:短期健康调查(SF-36),圣乔治呼吸问卷(SGRQ),基线呼吸困难指数(BDI),疲劳评估量表(FAS),莱斯特咳嗽问卷(LCQ),以及患者的需求和期望作者的调查。
■患者最重要的需求是获得新疗法,快速方便地进入专门从事IPF治疗的医疗中心,以及总体状况的改善或水平的维持。这些需求并没有随着时间而改变,除了治疗12个月后决定疾病管理的重要权利(p=0.014).吡非尼酮治疗1年后,SF-36的生活质量,身体累积评分(p=0.004)和精神累积评分(p=0.003)显著改善。观察到身体疼痛和活力的显着恶化。对于剩余的问卷(SGRQ,BDI,FAS,和LCQ),在研究过程中未发现显著变化.接受吡非尼酮治疗的患者中约有十分之一在所有领域均实现了一般症状改善;也就是说,生活质量的改善以及咳嗽和呼吸困难的减少。
■根据SF-36问卷,一年的抗纤维化治疗导致生活质量的总体改善。患者对疾病管理的期望没有改变;此外,获得新疗法和轻松进入专门从事IPF管理的健康中心仍然是他们的首要需求。
UNASSIGNED: Antifibrotic therapies reduce lung function decline in patients with idiopathic pulmonary fibrosis (IPF). This single-arm, open-label, nonrandomized study aimed to determine the influence of antifibrotic treatment on patients\' reported symptoms and expectations of the therapy.
UNASSIGNED: Fifty-two patients with confirmed IPF at a mean age of 65 ± 8.63 years (73% male) completed the following surveys at baseline and after 12 months of Pirfenidone treatment: Short Form Healthy Survey (SF-36), St. George\'s Respiratory Questionnaire (SGRQ), Baseline Dyspnea Index (BDI), Fatigue Assessment Scale (FAS), Leicester Cough Questionnaire (LCQ), and Patient\'s Needs and Expectations Authors\' Survey.
UNASSIGNED: The most important patients\' needs were access to novel therapy, fast and easy access to health centers specializing in IPF treatment, and the improvement of the general condition or the maintenance of its level. These needs did not change with time, except for the significantly more important right of deciding on disease management after 12 months of treatment (p = 0.014). The quality of life per SF-36, after 1 year of Pirfenidone treatment, significantly improved in the physical cumulative score (p = 0.004) and mental cumulative score (p = 0.003). Significant deteriorations were observed in bodily pain and vitality. For the remaining questionnaires (SGRQ, BDI, FAS, and LCQ), no significant changes in the course of the study were noticed. Around one in 10 patients subjected to Pirfenidone therapy had achieved general symptom improvement in all areas; that is, quality of life improvement as well as cough and dyspnea reduction.
UNASSIGNED: One year of antifibrotic treatment resulted in a general improvement in the quality of life per the SF-36 questionnaire. Patients\' expectations of disease management did not change; also, access to novel therapies and easy access to health centers specializing in IPF management remained their top needs.